Aging, Год журнала: 2024, Номер unknown
Опубликована: Авг. 1, 2024
Cholangiocarcinoma (CCA) is one of the most deadly cancers in world. It usually has a bad prognosis and challenging to identify its early stages. Long noncoding RNAs (lncRNAs) have been shown an increasing number studies be important control signaling pathways, cell behaviors, epigenetic modification that contribute growth tumors. The purpose this work was examine relationship between CCA lncRNA AL161431.1.
Язык: Английский
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Год журнала: 2025, Номер unknown, С. 189329 - 189329
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0
Clinical and Experimental Medicine, Год журнала: 2024, Номер 24(1)
Опубликована: Авг. 14, 2024
Cholangiocarcinoma (CCA) is a rare type of digestive tract cancer originating from the epithelial cells liver and biliary tract. Current treatment modalities for CCA, such as chemotherapy radiation therapy, have demonstrated limited efficacy in enhancing survival rates. Despite revolutionary potential immunotherapy management, its application CCA remains restricted due to minimal infiltration immune these tumors, rendering them cold unresponsive checkpoint inhibitors (ICIs). Cancer within tumors deploy various mechanisms evading attack, thus impeding clinical management. Recently, combination has become increasingly essential comprehend underlying enhance deficient antitumor response. Therefore, thorough understanding knowledge on imperative leverage benefits treating patients. Moreover, gut microbiota plays an role immunotherapeutic responses CCA. In this review, we summarize current concepts clarify intricate dynamics tumor microenvironment (TIME) We also delve into evasion employed by against anti-tumor responses. The context immunotherapies igniting critical function prompting been annotated. Furthermore, proposed future directions realm immunotherapy, aiming improve prognosis
Язык: Английский
Процитировано
2
Journal of Clinical Oncology, Год журнала: 2024, Номер unknown
Опубликована: Окт. 18, 2024
PURPOSE Biliary tract cancers (BTCs) harbor an immunosuppressed tumor microenvironment and respond poorly to PD-1/PD-L1 inhibitors. Bevacizumab (anti–vascular endothelial growth factor) plus chemotherapy can promote anticancer immunity, augmenting response PD-L1 inhibition. PATIENTS AND METHODS This randomized, double-blind, proof-of-concept phase II study enrolled patients (n = 162) with previously untreated advanced BTC (IMbrave151; ClinicalTrials.gov identifier: NCT04677504 ). Patients were randomly assigned 1:1 receive cycles of atezolizumab (1,200 mg) bevacizumab (15 mg/kg) or placebo once every 3 weeks until disease progression unacceptable toxicity. All received cisplatin (25 mg/m 2 ) gemcitabine (1,000 ; [CisGem]) on days 1 8 for up eight cycles. Stratification was by status, geographic region, primary location. The end point progression-free survival (PFS). No formal hypothesis testing performed. Exploratory correlative biomarker analysis undertaken using transcriptome 95) mutation profiling 102) baseline samples. RESULTS Between February September 2021, 162 enrolled. Median PFS 8.3 months in the arm 7.9 (stratified hazard ratio [HR], 0.67 [95% CI, 0.46 0.95]). overall (OS) 14.9 14.6 arms, respectively HR, 0.97 0.64 1.47]). incidence grade 4 adverse events 74% both arms. High VEGFA gene expression associated improved (HR, 0.44 0.23 0.83]) versus placebo. CONCLUSION In unselected BTC, adding CisGem modestly improves but not OS. may represent a predictive benefit from atezolizumab/bevacizumab, warranting further investigation.
Язык: Английский
Процитировано
2
Cancers, Год журнала: 2024, Номер 16(20), С. 3542 - 3542
Опубликована: Окт. 20, 2024
Treatment options for intrahepatic cholangiocarcinoma (iCCA), a highly malignant tumor with poor prognosis, are limited. Recent developments in immunotherapy and immune checkpoint inhibitors (ICIs) have offered new hope treating iCCA. However, several issues remain, including the identification of reliable biomarkers response to ICIs immune-based combinations. Tumor microenvironment (TIME) these hepatobiliary tumors has been evaluated is under assessment this setting order boost efficacy convert immunologically "cold" "hot" tumors. Herein, review TIME ICCA its critical function immunotherapy. Moreover, paper also discusses potential avenues future research, novel targets emerging treatment plans aimed increase effectiveness survival rates iCCA patients.
Язык: Английский
Процитировано
2
Hepatoma Research, Год журнала: 2024, Номер unknown
Опубликована: Янв. 9, 2024
Cholangiocarcinoma (CCA) is a highly aggressive tumor of the biliary tree characterized by an intense desmoplastic microenvironment (TME). To date, treatment CCA remains challenging; resection only curative with high recurrence probability. Besides resection, therapeutic options have moved forward advent immunotherapies, but these remain limited and low effective. Our knowledge about cellular interplays in still fragmentary. An area currently emerging regarding potential role cancer cell plasticity genesis immunosuppressive microenvironment. The cells’ ability to acquire stemness properties disseminate through epithelial-mesenchymal transition (EMT) shape immune that supports progression attracting cells including myeloid-derived suppressor (MDSCs), regulatory T (Tregs), M2 macrophages, increasing expression inhibitory checkpoints such as PD-1/PD-L-1. EMT-inducing transcription factors (EMT-TF) recently emerged regulators immunity creating This review delves into molecular mechanisms underlying existing links between EMT/stemness microenvironment, well last discoveries CCA.
Язык: Английский
Процитировано
1
The Innovation Medicine, Год журнала: 2024, Номер 2(1), С. 100052 - 100052
Опубликована: Янв. 1, 2024
<p>Intrahepatic cholangiocarcinoma (ICC) is a rare hepatobiliary cancer that originates from the epithelium of intrahepatic bile duct. The various treatments for ICC, such as chemotherapy, radiotherapy, and locoregional therapy, confer only modest improvements in survival rates. Immunotherapy, although revolutionary treatment, has found limited application treatment ICCs due to “cold” nature these tumors, which marked by scant T-cell infiltration. This characteristic makes immune checkpoint inhibitors (ICIs) unsuitable majority ICC patients. Therefore, comprehensively understanding mechanisms underlying tumors crucial harnessing potential immunotherapy treating paper explores evasion complex tumor microenvironment ICC. study provides comprehensive overview therapeutic strategies aimed at activating cold enhancing their immunogenicity. Furthermore, promising targets vaccines adoptive cellular therapy context are discussed. endeavor strives reveal new pathways innovative strategies, with focus on overcoming key challenge triggering an effective response patients.</p>
Язык: Английский
Процитировано
1
Опубликована: Март 5, 2024
Intrahepatic cholangiocarcinoma (ICCA) is a malignant epithelial neoplasm characterized by biliary differentiation within the liver. ICCA molecularly heterogeneous and exhibits broad spectrum of histopathological features. It highly aggressive carcinoma with high mortality poor survival rates. ICCAs are classified into two main subtypes: small duct type large types. These tumor types have different cell origins clinicopathological numerous molecular alterations, including mutations in KRAS, TP53, IDH1/2, ARID1A, BAP1, BRAF, SAMD4, EGFR, FGFR2 fusion. Two subtypes–inflammation proliferation–have been proposed. Recent advances high-throughput assays using next-generation sequencing improved our understanding pathogenesis genetics. The diagnosis poses significant challenge for pathologists because its varied morphologies phenotypes. Accurate essential effective patient management prognostic determination. This article provides an updated overview pathology, focusing particularly on features, histological subtypes, diagnostic approaches.
Язык: Английский
Процитировано
1
Clinical Cancer Research, Год журнала: 2024, Номер 30(16), С. 3428 - 3437
Опубликована: Июнь 14, 2024
The purpose of this study was to evaluate the clinical benefits nivolumab with/without ipilimumab combined with stereotactic body radiotherapy (SBRT) in patients pretreated metastatic biliary tract cancer (mBTC).
Язык: Английский
Процитировано
1
Digestive Disease Interventions, Год журнала: 2024, Номер 08(04), С. 239 - 250
Опубликована: Июль 31, 2024
Abstract Cholangiocarcinomas (CCAs) are highly aggressive, primary liver cancers with rising incidence and mortality rates. The current 5-year overall survival is less than 20%. There no standardized screening protocols, diagnostic methods include serum biomarkers imaging techniques suboptimal sensitivities specificities. most commonly used treatment options, including combination systemic therapies, locoregional surgical resection, offer improving but nonetheless limited progression-free survival. Liver transplantation has shown promising results as a potentially curative for two types of CCA, namely, perihilar intrahepatic. However, the evidence largely from retrospective series small to moderate sample sizes. need define optimal sequencing neoadjuvant adjuvant peritransplant well criteria CCA patient transplant eligibility. Here, we conduct granular review available on every step care pathway intrahepatic patients. We aim inform best practices future avenues research maximize number patients eligible this life-prolonging therapy.
Язык: Английский
Процитировано
1
Frontiers in Immunology, Год журнала: 2024, Номер 15
Опубликована: Сен. 3, 2024
Currently, the prognosis of advanced intrahepatic cholangiocarcinoma (ICC) is poor, and current treatment methods are not effective.
Язык: Английский
Процитировано
1